Clinical Trial · NCT05048810

Clinical Application of 68Ga-DOTA-NT-20.3 in the Early Diagnosis of Pancreatic Ductal Adenocarcinoma

Overview

The purpose of this study is to determine the pharmacokinetics, dosimetry, tolerance, tumor detection rate of 68Ga-DOTA-NT-20.3 in patient with pancreatic ductal adenocarcinoma (PDAC).

Sponsor

Nanjing First Hospital, Nanjing Medical University

Phase

N/A

Contacts

Feng Wang, Ph.D (STUDY_DIRECTOR)

ClinicalTrials.gov

NCT05048810

Drug / Compound

DOTA-NT-20.3

Isotope(s):

Target(s):

NTSR-1

Ligand Class: Peptides

Chelator: DOTA

Eligibility

Inclusion

patient with complete clinical data.
patient with pathohistologically proven localized or metastatic PDAC;

Exclusion

patient who cannot stay on PET/CT camera for app. 90 minutes;
patient who cannot stand MRI;
patient with other active cancer;
patient with serious mental, neurological, cardiovascular, respiratory and other system diseases;
patient with PDAC under the treatment blocking NT receptors;
patient simultaneously participating in another clinical trial;
pregnant or lactating women;
patient with severe severe refractory mental disorder.
patient with HIV, HCV, HVB infection or other serious chronic infection
patient with liver and kidney function (GFR less than 50 ml/min) disease;